Clinical Trials
20 trialsNCT04649359 2026-05-19
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Pfizer
Phase 2 Active not recruiting
NCT02952508 2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2 Active not recruiting
NCT05228470 2026-01-06
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Phase 2 Completed
NCT02899052 2025-08-05
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
AbbVie
Phase 2 Active not recruiting
NCT04782687 2025-01-16
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
US Oncology Research
Phase 2 Active not recruiting
NCT00017433 2020-10-06
Arsenic Trioxide in Treating Patients With Multiple Myeloma
CTI BioPharma
Phase 2 Terminated
NCT00017069 2020-10-05
Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
CTI BioPharma
Phase 2 Terminated
NCT00473590 2017-06-14
AMBER
Genentech, Inc.
Phase 2 Completed
NCT00721734 2017-05-02
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Amgen
Phase 2 Completed
NCT00256880 2017-01-18
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
GlaxoSmithKline
Phase 2 Completed
NCT01242930 2016-05-12
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
Geron Corporation
Phase 2 Completed
NCT00431340 2015-07-08
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Valerio Therapeutics
Phase 2 Terminated
NCT00402181 2014-05-14
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
Centocor, Inc.
Phase 2 Completed
NCT01500161 2013-11-25
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
Phase 2 Terminated
NCT00022282 2013-02-28
AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma
AEterna Zentaris
Phase 2 Completed
NCT00242827 2012-08-23
Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Terminated
NCT00087867 2010-10-18
Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
Scios, Inc.
Phase 2 Completed
NCT00229203 2009-12-24
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
PharmaMar
Phase 2 Completed
NCT00095277 2009-03-13
Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer
Amgen
Phase 2 Completed
NCT00096837 2006-06-08
A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
Pharmacyclics LLC.
Phase 2 Completed